T Cell Polarization Identifies Distinct Clinical Phenotypes in Scleroderma Lung Disease
Overview
Authors
Affiliations
Objective: Lung involvement is the leading cause of morbidity and mortality in systemic sclerosis (SSc; scleroderma), and interstitial lung disease (ILD) is the most common pulmonary manifestation. An abnormal profibrotic Th2/Tc2-polarized T cell response is postulated to mediate tissue damage and fibrosis. The aim of this study was to investigate whether a polarized T cell phenotype in SSc is associated with lung disease or other clinical manifestations of SSc.
Methods: Circulating T cells were characterized by flow cytometry in 62 patients with SSc and 36 healthy control subjects, using antibodies against CD3, CD4, CD8, chemokine receptor CCR5 (Th1/Tc1-specific), and prostaglandin D2 receptor CRTH2 (Th2/Tc2-specific). The ratio between CCR5 and CRTH2 T cell frequencies was used to quantify type 1 (high-ratio) or type 2 (low-ratio) immune polarization.
Results: Patients with SSc exhibited lower CCR5/CRTH2 T cell ratios than those exhibited by control subjects (P<0.0001), indicating a Th2/Tc2-polarized phenotype. Markedly reduced CCR5/CRTH2 T cell ratios were observed in SSc patients with ILD compared with SSc patients without ILD (P<0.0001), particularly in patients with active ILD (P<0.0001) compared with those with stable lung function. Lower CCR5/CRTH2 ratios were strongly associated with a lower value for the percent predicted forced vital capacity (P<0.0001). In patients with an estimated right ventricular systolic pressure>35 mm Hg, suggestive of pulmonary vascular disease, a lower value for the percent predicted diffusing capacity (DLCO) was associated with higher CCR5/CRTH2 T cell ratios (Th1/Tc1) (P=0.009), while in those with right ventricular systolic pressure<35 mm Hg, a lower value for the percent predicted DLCO correlated with lower ratios (Th2/Tc2) (P<0.0001), as observed for ILD.
Conclusion: T cell polarization in SSc is strongly associated with specific manifestations of lung disease. Measurement of T cell polarization may represent a valuable tool to monitor disease activity and predict clinical outcomes in SSc patients with lung disease.
Renaud L, Wilson C, Lafyatis R, Schnapp L, Feghali-Bostwick C iScience. 2024; 27(6):110010.
PMID: 38868196 PMC: 11167435. DOI: 10.1016/j.isci.2024.110010.
Petelytska L, Bonomi F, Cannistra C, Fiorentini E, Peretti S, Torracchi S RMD Open. 2023; 9(4).
PMID: 37940340 PMC: 10632935. DOI: 10.1136/rmdopen-2023-003426.
Novel Therapeutic Strategies in the Treatment of Systemic Sclerosis.
Gumkowska-Sroka O, Kotyla K, Mojs E, Palka K, Kotyla P Pharmaceuticals (Basel). 2023; 16(8).
PMID: 37630981 PMC: 10458905. DOI: 10.3390/ph16081066.
Type 2 cytokines and scleroderma interstitial lung disease.
Pellicano C, Vantaggio L, Colalillo A, Pocino K, Basile V, Marino M Clin Exp Med. 2023; 23(7):3517-3525.
PMID: 37392249 PMC: 10618297. DOI: 10.1007/s10238-023-01125-x.
Padilla C, Valenzi E, Tabib T, Nazari B, Sembrat J, Rojas M Rheumatology (Oxford). 2023; 63(3):837-845.
PMID: 37310903 PMC: 10907815. DOI: 10.1093/rheumatology/kead273.